Literature DB >> 18679181

Nonprofit biomedical companies.

R M Conti1, D O Meltzer, M J Ratain.   

Abstract

Nonprofit biomedical firms are an integrated market-based solution to improve incentives for investment in promising scientific areas that have high social value but minimal potential for profit. We briefly review the current market with an emphasis on the financing of innovative product development and propose ideas for new nonprofit companies centered on the health concerns of developed countries. We conclude with a suggestion that opportunities exist for nonprofit firms focused on cancer diagnostics, given the limitations of current financing incentives and ripe scientific opportunity.

Entities:  

Mesh:

Year:  2008        PMID: 18679181      PMCID: PMC4591870          DOI: 10.1038/clpt.2008.123

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  5 in total

1.  Oxymoron no more: the potential of nonprofit drug companies to deliver on the promise of medicines for the developing world.

Authors:  Victoria G Hale; Katherine Woo; Helene Levens Lipton
Journal:  Health Aff (Millwood)       Date:  2005 Jul-Aug       Impact factor: 6.301

Review 2.  Economics of new oncology drug development.

Authors:  Joseph A DiMasi; Henry G Grabowski
Journal:  J Clin Oncol       Date:  2007-01-10       Impact factor: 44.544

3.  Estimating the cost of new drug development: is it really 802 million dollars?

Authors:  Christopher P Adams; Van V Brantner
Journal:  Health Aff (Millwood)       Date:  2006 Mar-Apr       Impact factor: 6.301

4.  Obstacles and opportunities in new drug development.

Authors:  K I Kaitin
Journal:  Clin Pharmacol Ther       Date:  2008-02       Impact factor: 6.875

5.  Market incentives and pharmaceutical innovation.

Authors:  Wesley Yin
Journal:  J Health Econ       Date:  2008-02-17       Impact factor: 3.883

  5 in total
  4 in total

1.  The critical need for alternative antiretroviral formulations, and obstacles to their development.

Authors:  Susan Swindells; Charles Flexner; Courtney V Fletcher; Jeffrey M Jacobson
Journal:  J Infect Dis       Date:  2011-07-25       Impact factor: 5.226

2.  Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients.

Authors:  Ezra E W Cohen; Kehua Wu; Christine Hartford; Masha Kocherginsky; Kimberly Napoli Eaton; Yuanyuan Zha; Anitha Nallari; Michael L Maitland; Kammi Fox-Kay; Kristin Moshier; Larry House; Jacqueline Ramirez; Samir D Undevia; Gini F Fleming; Thomas F Gajewski; Mark J Ratain
Journal:  Clin Cancer Res       Date:  2012-08-07       Impact factor: 12.531

Review 3.  Non-profit Drug Research and Development at a Crossroads.

Authors:  Szymon Jarosławski; Mondher Toumi; Pascal Auquier; Claude Dussart
Journal:  Pharm Res       Date:  2018-02-07       Impact factor: 4.200

4.  Non-profit drug research and development: the case study of Genethon.

Authors:  Szymon Jarosławski; Mondher Toumi
Journal:  J Mark Access Health Policy       Date:  2018-11-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.